Ariflo
Ariflo Uses, Dosage, Side Effects, Food Interaction and all others data.
Ariflo (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). It is orally active and acts as a selective Phosphodiesterase-4 inhibitor. Following four clinical trials, the drug proved to be effective in treating COPD, however it has never been marketed due to a poor side effect profile.
| Trade Name | Ariflo |
| Generic | Cilomilast |
| Cilomilast Other Names | Ariflo, Cilomilast |
| Type | |
| Formula | C20H25NO4 |
| Weight | Average: 343.4168 Monoisotopic: 343.178358293 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in chronic obstructive pulmonary disease (COPD).
How Ariflo works
Ariflo shows high selectivity for cAMP-specific PDE4, an isoenzyme that predominates in pro-inflammatory and immune cells and that is 10-fold more selective for PDE4D than for PDE4A, -B or -C. In vitro, cilomilast suppresses the activity of several pro-inflammatory and immune cells that have been implicated in the pathogenesis of asthma and COPD. Moreover, it is highly active in animal models of these diseases. Ariflo has been shown to exert potent anti-inflammatory effects both in vitro and in vivo.
Innovators Monograph
You find simplified version here Ariflo
